Back to search

Article

Dapagliflozin improves early diabetic nephropathy by downregulating PPP2R2A and CXCL12/S100A13 through ROS- dependent

2022-05-10

Abstract excerpt

Diabetic nephropathy (DN) is a common chronic complication of diabetes mellitus (DM), and dapagliflozin, a representative drug of sodium-glucose co-transport protein 2 inhibitors (SGLT2i), is a novel hypoglycemic agent for the treatment of type 2 diabetes mellitus (T2DM), which has been shown to reverse microalbuminuria in early type 2 diabetic nephropathy (T2DN), but the mechanism of action remains to be elucidat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ed8c4365-6d14-5337-b51d-a7eba375296b
DOI
10.21203/rs.3.rs-1511213/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Dapagliflozin improves early diabetic nephropathy by downregulating PPP2R2A and CXCL12/S100A13 through ROS- dependentDOI 10.21203/rs.3.rs-1511213/v1
Select a neighboring publication to make it the new centre.